Table 1 Baseline characteristics of various subtypes of GH- producing pituitary adenoma patients
Variables | Single Staining n = 48 (%67.6) | Dual Staining n = 23(%32.4) | Total n = 71(100%) | ||
|---|---|---|---|---|---|
Densely granulated n = 34 (%47.9) | Sparsely granulated n = 14 (%19.7) | Total n = 48 (%67.6) |  |  | |
Demographic and Clinical data | |||||
 Mean age, yrs. (SD) | 40.9 ± 11.0 | 40.3 ± 10.9 | 40.7 ± 10.9 | 42.8 ± 10.3 | 41.4 ± 10.7 |
 Females, n (%) | 22(64.7) | 9(64.3) | 31(64.6) | 13(56.5) | 44(62.0) |
 Body mass index, mean (SD) | 27.1 ± 3.5 | 29.9 ± 5.9 | 27.9 ± 4.5 | 28.1 ± 3.9 | 28.0 ± 4.3 |
Clinical manifestations, n (%) | |||||
 Acromegalic Features | 30(88.2) | 13(92.9) | 43(89.5) | 21(91.3) | 64(90.1) |
 Headache | 18(52.9) | 8(57.1) | 26(54.2) | 16(69.6 | 42(59.2) |
 Oligoamenorrhea | 11(50.0) | 5(55.6) | 16(51.6) | 7(53.8) | 23(52.3) |
 Weight gain | 15(44.1) | 10(71.4) | 25(52.1) | 11(47.8) | 36(50.7) |
 Decreased libido | 16(47.1) | 7(50) | 23(47.9) | 10(43.5) | 33(46.5) |
 Visual Complaint | 13(38.2) | 6(42.9) | 19(39.6) | 13(56.5) | 32(45.1) |
 Hyper hydrosis | 13(38.2) | 3(21.4) | 16(33.3) | 7(30.4) | 23(32.4) |
 Hypertension | 9(26.5) | 2(14.3) | 11(22.9) | 6(26.1) | 17(23.9) |
 Diabetes mellitus | 4(11.8) | 3(21.4) | 7(14.6) | 5(21.7) | 12(16.9) |
 Weakness | 4(11.8) | 3(21.4) | 7(14.6) | 2(8.7) | 9(12.7) |
 Galactorrhea | 5(14.7) | 1(7.1) | 6(12.5) | 2(8.7) | 8(11.3) |
Hypopituitarism, n (%) | |||||
 Central hypogonadism | 19(55.9) | 10(71.4) | 29(60.4) | 14(60.9) | 43(60.6) |
 Central hypothyroidism | 1(2.9) | 2(14.3) | 3(6.2) | 0(0) | 3(4.2) |
 Central adrenal insufficiency | 1(2.9) | 0(0) | 1(1.4) | 0(0) | 1(1.4) |
Biochemical profile (Before surgery) | |||||
 Median prolactin level, ng/ml (IQR) | 21(11.9–34.2) | 25(17.2–43) | 24(13.1–34) | 32(14–56) | 25(13.4–40.0) |
 Prolactin elevated, n (%) | 18(52.9) | 9(64.3) | 27(56.2) | 14(60.9) | 41(57.7) |
 Median IGF-1 level, ng/ml (IQR) | 615(524.7–784.7) | 692.5(470.2–950.5) | 631.5(520.2–839.5) | 651(439–860) | 633(488–850) |
 Mean GH level, ng/ml (SD) †| 17.6 ± 17.1 | 11.5 ± 5.9 | 15.8 ± 14.9 | 14.6 ± 14.5 | 15.4 ± 14.7 |
MRI Tumor characteristics | |||||
 Size | |||||
  Mean diameter, mm (SD) | 17.9 ± 9.0 | 24.4 ± 10.9 | 19.8 ± 9.9 | 16.97 ± 10.1 | 18.8 ± 10.0 |
  Macroadenoma, n (%) | 29(85.3) | 13(92.9) | 42(87.5) | 19(82.6) | 61(85.9) |
  Size-group > 17 mm, n (%) | 17(50.0) * | 11(78.6) * | 28(58.3) | 8(34.8) * | 36(50.7) |
 Extrasellar extension | |||||
  Suprasellar extension, n (%) | 24(70.6) | 12(85.7) | 36(75) | 13(56.5) | 49(69.0) |
  Cavernous sinus invasion, n (%) | 6(18.2) | 6(42.9) | 12(25.5) | 4(17.4) | 16(22.9) |
  Infrasellar invasion, n (%) | 7(20.6) | 6(42.9) | 13(27.1) | 9(39.1) | 22(31.0) |
 T2- MRI Intensity, n (%) | |||||
  Iso or hyper-intense‡ | 10(58.8) | 7(87.5) | 17(68.0) | 6(66.7) | 23(67.6) |
  Hypo-intense | 7(41.2) | 1(12.5) | 8(32.0) | 3(33.3) | 11(32.4) |
Pathological Tumor characteristics | |||||
 Mean of Ki-67 (SD) | 1.80 (1.59) | 2.33 (1.40) | 1.96 (1.54) | 1.84 (1.21) | 1.93 (1.45) |
 Ki-67 > 3% (SD), n (%) | 6(18.8) | 5(41.7) | 11(25.0) | 3(17.6) | 14(23.0) |
 P53 Positive††, n (%) | 6(21.4) | 6(60) | 12(31.6) | 3(17.6) | 15(27.3) |